NO20054441L - G-laktamderivater som prostaglandinagonister - Google Patents
G-laktamderivater som prostaglandinagonisterInfo
- Publication number
- NO20054441L NO20054441L NO20054441A NO20054441A NO20054441L NO 20054441 L NO20054441 L NO 20054441L NO 20054441 A NO20054441 A NO 20054441A NO 20054441 A NO20054441 A NO 20054441A NO 20054441 L NO20054441 L NO 20054441L
- Authority
- NO
- Norway
- Prior art keywords
- lactam derivatives
- prostaglandin agonists
- prostaglandin
- agonists
- lactam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Den foreliggende oppfinnelsen angår y-laktamderivater, da spesielt for anvendelse som medikamenter, så vel som farmasøytiske preparater og sammensetninger som inneholder slike y-laktamderivater.Nevnte y-derivater kan brukes ved behandlingen og/eller for å forebygge astma, hypertensjon, osteoporose, seksuell dysfunksjon eller fruktbarhetslidelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45182903P | 2003-03-03 | 2003-03-03 | |
PCT/EP2004/050239 WO2004078103A2 (en) | 2003-03-03 | 2004-03-02 | G-lactam derivatives as prostaglandin agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20054441L true NO20054441L (no) | 2005-09-26 |
Family
ID=32962645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054441A NO20054441L (no) | 2003-03-03 | 2005-09-26 | G-laktamderivater som prostaglandinagonister |
Country Status (11)
Country | Link |
---|---|
US (1) | US7276531B2 (no) |
EP (1) | EP1603874B1 (no) |
JP (1) | JP4662926B2 (no) |
AR (1) | AR043450A1 (no) |
AT (1) | ATE394372T1 (no) |
AU (1) | AU2004216857A1 (no) |
CA (1) | CA2513652A1 (no) |
DE (1) | DE602004013559D1 (no) |
ES (1) | ES2305779T3 (no) |
NO (1) | NO20054441L (no) |
WO (1) | WO2004078103A2 (no) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7547685B2 (en) | 2004-11-08 | 2009-06-16 | Allergan, Inc. | Therapeutic substituted pyrrolidone compounds |
EP2308510B1 (en) | 2005-06-03 | 2016-03-16 | Ono Pharmaceutical Co., Ltd. | Agent for regeneration and/or protection of nerves |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
NZ704171A (en) * | 2012-07-19 | 2017-10-27 | Cayman Chemical Co Inc | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
KR102221534B1 (ko) * | 2012-08-21 | 2021-02-26 | 알레간 인코포레이티드 | 치환된 감마 락탐의 합성을 위한 공정 |
EP3235817B1 (en) * | 2013-03-15 | 2018-12-12 | Cayman Chemical Company, Incorporated | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
CA2903314C (en) | 2013-03-15 | 2023-02-14 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
CA2910398A1 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
WO2018015278A1 (en) | 2016-07-21 | 2018-01-25 | Unilever Plc | Lactams for use in the treatment of skin lesions |
US11160787B2 (en) | 2016-07-21 | 2021-11-02 | Conopco, Inc. | 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections |
BR112019001134A2 (pt) | 2016-07-21 | 2019-04-30 | Unilever N.V. | uso de lactama e composição farmacêutica |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU198503B (en) | 1987-03-24 | 1989-10-30 | Chinoin Gyogyszer Es Vegyeszet | Process for producing triphenyl phosphonium salts |
SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
EP1042283B1 (en) | 1997-12-25 | 2004-02-25 | Ono Pharmaceutical Co., Ltd. | Omega-cycloalkyl-prostaglandin e2 derivatives |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6235780B1 (en) * | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
WO2000015608A1 (en) | 1998-09-14 | 2000-03-23 | Ono Pharmaceutical Co., Ltd. | φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT |
US20010006980A1 (en) * | 1998-10-15 | 2001-07-05 | Harada Shun-Ichi | Methods for stimulating bone formation |
MXPA02006322A (es) | 1999-12-22 | 2002-12-13 | Pfizer Prod Inc | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
DK1339678T3 (da) | 2000-11-27 | 2008-02-04 | Pfizer Prod Inc | Selektive agonister til EP4-receptor til behandling af osteoporose |
JP2004521954A (ja) | 2001-07-16 | 2004-07-22 | エフ.ホフマン−ラ ロシュ アーゲー | Ep4受容体作用薬としてのプロスタグランジン類似体 |
MXPA04000454A (es) * | 2001-07-16 | 2004-03-18 | Hoffmann La Roche | Derivados de 2-pirrolidona como agonistas de prostanoides. |
-
2004
- 2004-03-02 EP EP04737283A patent/EP1603874B1/en not_active Expired - Lifetime
- 2004-03-02 US US10/547,676 patent/US7276531B2/en not_active Expired - Fee Related
- 2004-03-02 WO PCT/EP2004/050239 patent/WO2004078103A2/en active IP Right Grant
- 2004-03-02 CA CA002513652A patent/CA2513652A1/en not_active Abandoned
- 2004-03-02 AR ARP040100655A patent/AR043450A1/es not_active Application Discontinuation
- 2004-03-02 ES ES04737283T patent/ES2305779T3/es not_active Expired - Lifetime
- 2004-03-02 AU AU2004216857A patent/AU2004216857A1/en not_active Abandoned
- 2004-03-02 AT AT04737283T patent/ATE394372T1/de not_active IP Right Cessation
- 2004-03-02 DE DE602004013559T patent/DE602004013559D1/de not_active Expired - Lifetime
- 2004-03-02 JP JP2006505441A patent/JP4662926B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-26 NO NO20054441A patent/NO20054441L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4662926B2 (ja) | 2011-03-30 |
AR043450A1 (es) | 2005-07-27 |
WO2004078103A3 (en) | 2004-10-28 |
US20060194865A1 (en) | 2006-08-31 |
ES2305779T3 (es) | 2008-11-01 |
WO2004078103A2 (en) | 2004-09-16 |
EP1603874A2 (en) | 2005-12-14 |
JP2006519245A (ja) | 2006-08-24 |
DE602004013559D1 (de) | 2008-06-19 |
ATE394372T1 (de) | 2008-05-15 |
CA2513652A1 (en) | 2004-09-16 |
AU2004216857A1 (en) | 2004-09-16 |
EP1603874B1 (en) | 2008-05-07 |
US7276531B2 (en) | 2007-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054441L (no) | G-laktamderivater som prostaglandinagonister | |
SE0301010D0 (sv) | Novel compounds | |
SE0301009D0 (sv) | Novel compounds | |
NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
SE0302760D0 (sv) | New compounds | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
NO20084489L (no) | Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
NO20075693L (no) | Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme | |
BR0208957A (pt) | Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc | |
NO20033732L (no) | N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser. | |
NO20065984L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
DK1703905T3 (da) | Indol-derivater og anvendelse deraf som kinaseinhibitorer, især IKK2-inhibitorer | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |